论文部分内容阅读
目的:观察多奈派齐联合尼莫地平治疗脑梗死后认知功能障碍的临床疗效。方法:将128例脑梗死后认知功能损害患者随机分为2组,治疗组予尼莫地平片30mg口服3次/日及多奈派齐片5mg口服1次/日,疗程12周;对照组仅予尼莫地平片30mg口服3次/日,疗程12周。观察两组治疗后血管性认知功能障碍的改善情况,并应用MOCA评价疗效。结果:治疗12周后,治疗组在定向力、记忆力、计算力、语言能力、执行力等项目的分值要高于对照组,差异有统计学意义(P<0.05)。结论:多奈派齐联合尼莫地平治疗脑梗死后认知障碍作用明显,早期应用可预防及延缓痴呆的发生。
Objective: To observe the clinical efficacy of Donepitch combined with nimodipine in the treatment of cognitive dysfunction after cerebral infarction. Methods: A total of 128 patients with cognitive impairment after cerebral infarction were randomly divided into two groups. The treatment group was given nimodipine 30mg orally three times a day and the doepaixi tablet 5mg orally a day for 12 weeks. Group only nimodipine tablets 30mg orally 3 times / day, treatment for 12 weeks. The improvement of vascular cognitive impairment after treatment in both groups was observed, and MOCA was used to evaluate the curative effect. Results: After 12 weeks of treatment, the score of the treatment group was higher than that of the control group in orientation, memory, calculating ability, language ability and executive ability. The difference was statistically significant (P <0.05). Conclusion: Donepiti combined with nimodipine has obvious effect on cognitive impairment after cerebral infarction. Early application can prevent and delay dementia.